Chamber and committees

This information is not held centrally.

This information is not held centrally.

This information is not held centrally.

NHS boards will use locum perfusionists in cases where they have been unable to recruit permanent staff through recruitment. An action plan for perfusionists has been developed and is currently under discussion between the Scottish government and NHS Scotland employers.

It is expected that private providers will follow the guidance issued by the Chief Medical Officer during 2012 and are expected to provide a clinically appropriate package of care to their patients. The first port of call for all patients who have undergone breast augmentation in the private sector is their original provider.

NHSScotland boards are expected to follow workforce planning guidance as outlined in NHS CEL 32(2011). It is the responsibility of each health board to produce workforce plans on an annual basis and to take into consideration the training and development needs of their staff. Demand is based upon NHS board workforce projections for staffing groups while supply is determined by the current stock of trainees.

We are advised by the Golden Jubilee Hospital that its projection to recruit a trainee clinical perfusionist for academic year September 2014, forms part of its workforce planning arrangements, taking into account future succession planning, and potential plans to establish a national training centre or programme at the Golden Jubilee National Hospital for trainee clinical perfusionists.

NHS Education for Scotland have advised that there was no note taken of the discussion between the Healthcare Science Programme Manager at NHS Education for Scotland and the President of the College of Clinical Perfusion Scientists of Great Britain and Ireland.

NHS Lothian is the only board in Scotland who have applied for a recruitment and retention premium for perfusionists. In order to put a recruitment and retention premium in place, an NHS board must apply through the agreed procedure, providing evidence to support the application. This is then considered by the Scottish Terms and Conditions Committee, the partnership body which oversees the Agenda for Change system in Scotland.

I requested a meeting with the Secretary of State for Health on 15 January 2013 to discuss value based pricing and its impact on access to new medicines in Scotland. My request for a meeting was subsequently passed to Earl Howe, Parliamentary Under Secretary of State for Quality.

This information is not centrally collected.